Swedish biotechnology company Diamyd Medical AB (Nasdaq First North Growth Market:DMYD-B) on Tuesday announced that the South Korean Patent Office has granted a patent for the use of insulin-based antigens to treat autoimmune diabetes in patients with the HLA DR4-DQ8 genetic marker.
This patent, valid until 2035, is the first of its kind globally and reinforces the importance of precision medicine in diabetes care.
Diamyd Medical is currently conducting a Phase 3 trial with its GAD-specific immunotherapy Diamyd in patients with HLA DR3-DQ2, another genetically distinct subgroup of Type 1 diabetes patients.
Up to 90% of Type 1 diabetes patients carry either the HLA DR3-DQ2 or HLA DR4-DQ8 genetic markers.
Breckenridge Pharmaceutical launches FDA approved methadone injection
Hansa Biopharma reports positive Phase 2 imlifidase results
Nona Biosciences signs research collaboration and licence agreement with Candid Therapeutics
Gilead Sciences secures positive CHMP opinion for seladelpar in PBC treatment
Full Circles Therapeutics advances non-viral gene editing innovation
Hansa Biopharma completes enrolment in anti-GBM disease trial
Transposon Therapeutics acquires portfolio of novel nucleoside analogues from PrimeFour Therapeutics
Adicet Bio doses first patient in Phase 1 trial of ADI-001 for lupus nephritis
Pulmatrix announces merger with Cullgen to advance targeted protein degradation
Faron Pharmaceuticals files patent for soluble Clever-1 in autoimmune disease treatment
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant